PTC Therapeutics (PTCT) Tops Q3 EPS by 19c

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.03), $0.19 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $23 million versus the consensus estimate of $19.76 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)